The researchers reviewed 467 individuals from the Prospective Metabolism and Islet Cell Evaluation (PROMISE) trial. Participants were aged between 40 and 60 years old and did not have diabetes at the start of the study. The participants, which were recruited from Toronto and London, in Ontario, Canada, were chosen as patients having at least one or more risk factors of developing type 2 diabetes. They were monitored over a 3 year period.

The results outline that people with prediabetes are at a higher risk of neuropathy than the general population and that monitoring for signs of nerve damage should be carried out to reduce the risks of foot damage and the potential consequences that can result.